Cargando…

Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial

BACKGROUND: Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hylander, Terese, Larsson, Olivia, Petersson-Westin, Ulla, Eriksson, Mia, Kumlien Georén, Susanna, Winqvist, Ola, Cardell, Lars-Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728811/
https://www.ncbi.nlm.nih.gov/pubmed/26817454
http://dx.doi.org/10.1186/s12931-016-0324-9
_version_ 1782412183889510400
author Hylander, Terese
Larsson, Olivia
Petersson-Westin, Ulla
Eriksson, Mia
Kumlien Georén, Susanna
Winqvist, Ola
Cardell, Lars-Olaf
author_facet Hylander, Terese
Larsson, Olivia
Petersson-Westin, Ulla
Eriksson, Mia
Kumlien Georén, Susanna
Winqvist, Ola
Cardell, Lars-Olaf
author_sort Hylander, Terese
collection PubMed
description BACKGROUND: Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT. METHODS: Thirty-six patients with pollen-induced rhinoconjunctivitis were randomised to receive three intralymphatic inguinal injections of active allergen (1000 SQ-U birch- or grass-pollen) or placebo. Clinical effects, safety and circulating immunological markers were assessed before, 4 weeks after treatment and at the end of the consecutive pollen season. RESULTS: No moderate or severe reactions were recorded following ILIT. Patients receiving active ILIT experienced a significant improvement in self-recorded seasonal allergic symptoms, as compared to placebo (p = 0.05). In a subgroup of these patients (“improved”), a reduction in nasal symptoms following nasal allergen provocation was also demonstrated. No changes in total IgE or IgG(4) were found. However, the affinity of allergen specific IgG(4) following active treatment was significantly increased, as compared to non-improved patients (p = 0.04). This could be correlated with clinical improvement, on an individual level. CONCLUSIONS: This double-blinded placebo-controlled study confirms that ILIT is a safe and effective treatment for pollen-induced rhinoconjunctivitis, markedly reducing seasonal allergic symptoms. TRIAL REGISTRATION: EudraCT: 2009-016815-39 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12931-016-0324-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4728811
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47288112016-01-28 Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial Hylander, Terese Larsson, Olivia Petersson-Westin, Ulla Eriksson, Mia Kumlien Georén, Susanna Winqvist, Ola Cardell, Lars-Olaf Respir Res Research BACKGROUND: Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT. METHODS: Thirty-six patients with pollen-induced rhinoconjunctivitis were randomised to receive three intralymphatic inguinal injections of active allergen (1000 SQ-U birch- or grass-pollen) or placebo. Clinical effects, safety and circulating immunological markers were assessed before, 4 weeks after treatment and at the end of the consecutive pollen season. RESULTS: No moderate or severe reactions were recorded following ILIT. Patients receiving active ILIT experienced a significant improvement in self-recorded seasonal allergic symptoms, as compared to placebo (p = 0.05). In a subgroup of these patients (“improved”), a reduction in nasal symptoms following nasal allergen provocation was also demonstrated. No changes in total IgE or IgG(4) were found. However, the affinity of allergen specific IgG(4) following active treatment was significantly increased, as compared to non-improved patients (p = 0.04). This could be correlated with clinical improvement, on an individual level. CONCLUSIONS: This double-blinded placebo-controlled study confirms that ILIT is a safe and effective treatment for pollen-induced rhinoconjunctivitis, markedly reducing seasonal allergic symptoms. TRIAL REGISTRATION: EudraCT: 2009-016815-39 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12931-016-0324-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-27 2016 /pmc/articles/PMC4728811/ /pubmed/26817454 http://dx.doi.org/10.1186/s12931-016-0324-9 Text en © Hylander et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hylander, Terese
Larsson, Olivia
Petersson-Westin, Ulla
Eriksson, Mia
Kumlien Georén, Susanna
Winqvist, Ola
Cardell, Lars-Olaf
Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
title Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
title_full Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
title_fullStr Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
title_full_unstemmed Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
title_short Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
title_sort intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728811/
https://www.ncbi.nlm.nih.gov/pubmed/26817454
http://dx.doi.org/10.1186/s12931-016-0324-9
work_keys_str_mv AT hylanderterese intralymphaticimmunotherapyofpolleninducedrhinoconjunctivitisadoubleblindplacebocontrolledtrial
AT larssonolivia intralymphaticimmunotherapyofpolleninducedrhinoconjunctivitisadoubleblindplacebocontrolledtrial
AT peterssonwestinulla intralymphaticimmunotherapyofpolleninducedrhinoconjunctivitisadoubleblindplacebocontrolledtrial
AT erikssonmia intralymphaticimmunotherapyofpolleninducedrhinoconjunctivitisadoubleblindplacebocontrolledtrial
AT kumliengeorensusanna intralymphaticimmunotherapyofpolleninducedrhinoconjunctivitisadoubleblindplacebocontrolledtrial
AT winqvistola intralymphaticimmunotherapyofpolleninducedrhinoconjunctivitisadoubleblindplacebocontrolledtrial
AT cardelllarsolaf intralymphaticimmunotherapyofpolleninducedrhinoconjunctivitisadoubleblindplacebocontrolledtrial